ASH 2021 Highlights from Day 2 of ASH 2021! Dr. Brian Koffman gives up updates on the reversible non-covalently binding BTKi (Bruton’s tyrosine kinase inhibitor) pirtobrutinib (formerly LOXO-305), another reversable BTKi known as MK-1026 (formerly ARQ-531), 3-year follow-up data from the Ascend Trial: Acalabrutinib vs Rituximab plus Idelalisib or Bendamustine in Relapsed/Refractory CLL, as well as a study analyzing of the impact of del 17p and TP53 mutations on therapy outcomes with various agents, and much more! cllsociety.org/2021/12/ash-...
CLL Society ASH 2021 Highlights from Day 2 of ... - CLL Support
CLL Society ASH 2021 Highlights from Day 2 of ASH 2021! Dr. Brian Koffman gives up updates
Written by
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
Read more about...
4 Replies
•
Big thanks Brian for interpreting all those presentations for us, and a very big well done on the twelve years.
Best wishes,
Ernest
Thank you very much for listing these and explaining what they mean. Do you know if any of the time limited treatment programmes using novel agents suggest there is any possibility of recovery of the immune system?Thanks
A great summary again, thanks Brian
bkoffmanCLL CURE Hero
None seen yet.
Not what you're looking for?
You may also like...
CLL Society/ CAR-T! Read the story of Dr. Brian Koffman's 3 years of durable remission post-CAR-T!
remission here....
CLL SOCIETY'S ASH POSTER on our Free second opinion program plus two important papers from ASCO
ibrutinib or acalabrutib....
CLL Meets COVID Vaccines/ Dr. Brian Koffman's take
Dr. Koffman shares what we know, what we don't know and next steps here. https://cllsociety.org/2020
Urgent Message from Dr. Brian Koffman: Stop the spread of COVID-19!
Urgent Message from Dr. Brian Koffman: Stop the spread of COVID-19! Give your family and friends...